# US 2016/0355790 A1 · Influenza virus replication by inhibiting microrna lec7c binding to influenza viral crna and mrna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355790 A1
- Document ID: US20160355790A1
- Status: Published application
- Kind: A1
- Application number: 15/170,556
- Filed: 2016-06-01
- Published: 2016-12-08
- Earliest claimed: 2015-06-01
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Yoshihiro Kawaoka; Gabriele Neumann; Jihui Ping
- Web page: https://patentgrep.com/patent/US20160355790A1

## CPC

- C07K 14/005: from viruses
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 39/12: Viral antigens
- A61K 2039/525: {Virus}
- C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A vector, composition and method to improve influenza virus replication by inhibiting miRNA lec-7C binding to influenza virus mRNA and/or cRNA.

## Claims

### Claim 1

A recombinant vector comprising an influenza M gene segment having a nucleotide other than U/T at position 1011, a nucleotide other than G at position 1012, a nucleotide other than A at position 1013, a nucleotide other than U/T at position 1014, a nucleotide other than G at position 1015, a nucleotide other than G at position 1016, a nucleotide other than A at position 1017, or any combination thereof, wherein the numbering refers to cRNA+.

### Claim 2 (depends on 1)

The vector of claim 1 wherein the gene segment has a nucleotide other than G at position 1012, a nucleotide other than A at position 1013, and a nucleotide other than U at position 1014.

### Claim 3 (depends on 1)

The vector of claim 1 wherein the gene segment has at least two of a nucleotide other than G at position 1012, a nucleotide other than A at position 1013, or a nucleotide other than U at position 1014.

### Claim 4

A method to prepare influenza virus, comprising: contacting a cell with at least one of:
a vector comprising a promoter operably linked to an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, and a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence, wherein the mutant M cDNA has a nucleotide other than U/T at position 1011, a nucleotide other than G at position 1012, a nucleotide other than A at position 1013, a nucleotide other than U/T at position 1014, a nucleotide other than G at position 1015, a nucleotide other than G at position 1016, a nucleotide other than A at position 1017, or any combination thereof, wherein the numbering refers to cRNA+ and optionally wherein the cDNA for HA and/or NA has sequences for a heterologous HA or NA; and optionally
a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, and a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NP, and optionally a vector comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M1, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M2, or a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NS2.

### Claim 5 (depends on 4)

The method of claim 4 further comprising isolating the virus.

### Claim 6 (depends on 5)

Virus obtained by the method of claim 5.

### Claim 7 (depends on 5)

A cell infected with the virus of claim 5.

### Claim 8 (depends on 7)

The cell of claim 7 which is a cell in an embryonated egg.

### Claim 9 (depends on 7)

The cell of claim 7 which is a Vero cell.

### Claim 10

An isolated recombinant influenza virus comprising a viral segment for PB1, PB2, PA, and NP, a viral segment for M having a nucleotide other than U/T at position 1011, a nucleotide other than G at position 1012, a nucleotide other than A at position 1013, a nucleotide other than LIT at position 1014, a nucleotide other than G at position 1015, a nucleotide other than G at position 1016, a nucleotide other than A at position 1017, or any combination thereof, wherein the numbering refers to cRNA+, a viral segment for NS with a Glu residue at position 55, a viral segment for a heterologous NA, and a viral segment for a heterologous HA.

### Claim 11 (depends on 10)

The isolated recombinant influenza virus of claim 10 wherein the viral segment for PB1, PB2, PA, NS, M, and NP encode viral proteins having at least 90% amino acid sequence identity to proteins encoded by SEQ ID Nos. 1-6.

### Claim 12 (depends on 10)

The isolated recombinant influenza virus of claim 10 wherein the viral segment for HA is for H1, H3, H5 or H7.

### Claim 13 (depends on 10)

The isolated recombinant influenza virus of claim 10 wherein the viral segment for PB2 encodes a PB2 with a serine at position 360 and has substantially the same amino acid sequence and substantially the same activity as a corresponding polypeptide encoded by SEQ ID NO:3 but which viral segment does not encode a PB2 with SEQ ID NO:3.

### Claim 14 (depends on 10)

The isolated recombinant virus of claim 10 which has one or more but less than 20 substitutions or less than 25 substitutions relative to SEQ ID NO:3.

### Claim 15 (depends on 14)

The isolated recombinant of claim 14 wherein the one or more substitutions include conservative substitutions.

### Claim 16 (depends on 10)

The isolated recombinant influenza virus of claim 10 further comprising one or more of the following: 142N, 225C, 356R, or 550L in PA; 112G, 247H, 507V, or 644A in PB1; 202L, 323L or 504V in PB2; 74K, 112L, 116L, 417D, or 442A in NP; 97A and/or 100H in M1; and/or 55E and/or 140Q in NS1, or combinations thereof, and optionally at least one of 142N in PA1, 55K in NS1 or 97A and/or 100H in M1; or further comprising one or more of the following: 40I, 40L, 112G, 180W, 247H, 507V, or 644A in PB1; 202L and/or 323L in PB2; 74K, 112L, 116L, 377N, 417D, or 422L in NP; 30P, 55K, 118K, 161T or 140Q in NS1; 142N, 225C, 356R, 401K, or 550L in PA; or one or more of 247H in PB1; 202L and/or 323L in PB2; 74K in NP; 55E in NS1; or 142N in PA.

### Claim 17 (depends on 10)

The isolated recombinant virus of claim 10 which has a U at position 4 in the gene segment for any one of PB1, PB2 or PA.

### Claim 18 (depends on 10)

The isolated recombinant influenza virus of claim 10 wherein at least one of the PA, PB1, PB2, NP, NS, and M gene segments has a C to U promoter mutation.

### Claim 19 (depends on 11)

The isolated recombinant influenza virus of claim 11 wherein the PA, PB1, PB2, NP, NS, and M gene segments comprise sequences for at least one of the following: a PB 1 having the amino acid sequence encoded by SEQ ID NO:2 or PB1 with at least 95% amino acid sequence identity to the PB1 encoded by SEQ ID NO:2; a PB2 having the amino acid sequence encoded by SEQ ID NO:3 or PB2 with at least 95% amino acid sequence identity to the PB2 encoded by SEQ ID NO:3; a PA having the amino acid sequence encoded by SEQ ID NO:1 or PA with at least 95% amino acid sequence identity to the PA encoded by SEQ ID NO:1; a NP having the amino acid sequence encoded by SEQ ID NO:4 or NP with at least 95% amino acid sequence identity to the NP encoded by SEQ ID NO:4; a M having the amino acid sequence encoded by SEQ ID NO:5 or M with at least 95% amino acid sequence identity to the M encoded by SEQ ID NO:5; or a NS having the amino acid sequence encoded by SEQ ID NO:6 or NS with at least 95% amino acid sequence identity to the NS encoded by SEQ ID NO:6 or wherein the PA, PB1, PB2, NP, NS, and M gene segments comprise sequences for at least one of the following: a PB1 having the amino acid sequence encoded by SEQ ID NO:10 or PB1 with at least 95% amino acid sequence identity to the PB1 encoded by SEQ ID NO:10; a PB2 having the amino acid sequence encoded by SEQ ID NO:11 or PB2 with at least 95% amino acid sequence identity to the PB2 encoded by SEQ ID NO:11; a PA having the amino acid sequence encoded by SEQ ID NO:12 or PA with at least 95% amino acid sequence identity to the PA encoded by SEQ ID NO:12; a NP having the amino acid sequence encoded by SEQ ID NO:13 or NP with at least 95% amino acid sequence identity to the NP encoded by SEQ ID NO:13; a M having the amino acid sequence encoded by SEQ ID NO: 14 or M with at least 95% amino acid sequence identity to the M encoded by SEQ ID NO: 14; or a NS having the amino acid sequence encoded by SEQ ID NO:15 or NS with at least 95% amino acid sequence identity to the NS encoded by SEQ ID NO:15.

### Claim 20 (depends on 10)

A method to immunize an individual against a pathogen, comprising administering to the individual an amount of the virus of claim 10 effective to immunize the individual.
